Five Prime Therapeutics Inc. (FPRX) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) Comparing side by side

As Biotechnology companies, Five Prime Therapeutics Inc. (NASDAQ:FPRX) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) are our subject to contrast. And more specifically their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Five Prime Therapeutics Inc. 59.05M 6.86 130.91M -4.03 0.00
VistaGen Therapeutics Inc. N/A 0.00 20.02M -0.94 0.00

Demonstrates Five Prime Therapeutics Inc. and VistaGen Therapeutics Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 provides Five Prime Therapeutics Inc. and VistaGen Therapeutics Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Five Prime Therapeutics Inc. -221.69% -41.5% -33.9%
VistaGen Therapeutics Inc. 0.00% -328.5% -187.7%

Risk & Volatility

Five Prime Therapeutics Inc. is 212.00% more volatile than Standard & Poor’s 500 due to its 3.12 beta. From a competition point of view, VistaGen Therapeutics Inc. has a -1.06 beta which is 206.00% more volatile compared to Standard & Poor’s 500.

Liquidity

The current Quick Ratio of Five Prime Therapeutics Inc. is 8.4 while its Current Ratio is 8.4. Meanwhile, VistaGen Therapeutics Inc. has a Current Ratio of 6.5 while its Quick Ratio is 6.5. Five Prime Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than VistaGen Therapeutics Inc.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for Five Prime Therapeutics Inc. and VistaGen Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Five Prime Therapeutics Inc. 0 0 3 3.00
VistaGen Therapeutics Inc. 0 0 0 0.00

The upside potential is 197.72% for Five Prime Therapeutics Inc. with average price target of $34.

Institutional & Insider Ownership

The shares of both Five Prime Therapeutics Inc. and VistaGen Therapeutics Inc. are owned by institutional investors at 88.3% and 11.6% respectively. 2.4% are Five Prime Therapeutics Inc.’s share owned by insiders. Comparatively, 2.47% are VistaGen Therapeutics Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Five Prime Therapeutics Inc. -5.84% 8.63% -7.43% -29.71% -47.75% -44.84%
VistaGen Therapeutics Inc. -1.67% -14.49% 28.26% 24.65% -12.81% 58.97%

For the past year Five Prime Therapeutics Inc. had bearish trend while VistaGen Therapeutics Inc. had bullish trend.

Summary

Five Prime Therapeutics Inc. beats on 6 of the 10 factors VistaGen Therapeutics Inc.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.